Trial · NCT03344341
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute change from baseline in HbA1c at Week 24 | At week 24 | Which will be derived using the HbA1c (%) at week 24 minus HbA1c (%) at baseline. |
| Secondary | Percentage of patients at Week 24 with reduction of HbA1c≥0.5%, body weight≥3% and SBP ≥3mmHg from baseline | From baseline to week 24 | Which will be derived using the number of patients who have reduction in HbA1c ≥ 5%, and body weight ≥3% and SBP ≥3 mmHg compared to baseline divided by the total number of patients. |
| Secondary | Percentage of patients achieving HbA1c<7.0% | From baseline to week 24 | Which will be derived using the number of patient who have the HbA1c (%) \< 7.0% after 24 weeks treatment divided by the total number of patients. |
| Secondary | Percentage of patients with reduction of HbA1c≥0.5% | From baseline to week 24 | Which will be derived using the number of patients who have reduction in HbA1c≥0.5% after 24 weeks compared to baseline divided by the total number of patients. |
| Secondary | Absolute change from baseline in fasting plasma glucose (FPG) | From baseline to week 24 | Which will be derived using the value of fasting plasma glucose (FPG) at post-baseline visits minus the value at baseline |
| Secondary | Absolute change from baseline in 2h postprandial glucose (PPG) | From baseline to week 24 | Which will be derived using the value of 2h postprandial glucose (PPG) at the post-baseline visits minus the value at baseline |
| Secondary | Absolute change from baseline in body weight | From baseline to week 24 | Which will be derived using the value of the body weight at the post-baseline visits minus the value at baseline |
| Secondary | Percentage of patients with reduction of body weight ≥3% | From baseline to week 24 | Which will be derived using the number of patients who have reduction in body weight≥3% after 24 weeks compared to baseline divided by the total number of patients. |
| Secondary | Absolute change from baseline in systolic blood pressure (SBP) | From baseline to week 24 | Which will be derived using the value of the systolic blood pressure at the post-baseline visits minus the value at baseline |
| Secondary | Percentage of patients with reduction of SBP ≥3 mmHg | From baseline to week 24 | Which will be derived using the number of patients who have reduction in SBP ≥3 mmHg after 24 weeks compared to baseline divided by the total number of patients. |
| Other | Homeostasis model assessment-β | From baseline to week 24 | Which will be used to evaluate the beta cell function. |
| Other | HOMA-IR | From baseline to week 24 | Which will be used to evaluate the insulin sensitivity |
| Other | The difference of the number between tablets taken and tablets prescribed | From baseline to week 24 | Which will be derived using the number of tablets dispensed minus the number of tablets returned |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03344341/registered